Publicaciones en las que colabora con María Luisa Gómez-Lus Centelles (25)

2015

  1. Diversidad genotípica y fenotípica en Enterococcus faecalis: ¿Es la invasión en agar un marcador de patogenicidad?

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 2, pp. 101-108

2014

  1. Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress

    Journal of Neuroinflammation, Vol. 11

2013

  1. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 10, pp. 2291-2295

  2. ¿Es la cuantificación del biofilm un elemento diferenciador en la patogenia de bacilos gramnegativos?

    Revista Espanola de Quimioterapia, Vol. 26, Núm. 2, pp. 97-102

2012

  1. Discordancia en los resultados de sensibilidad mediante método de difusión en agar de aislados de Pseudomonas aeruginosa en pacientes con fibrosis quística tras pre-incubación anaerobia y su potencial relevancia clínica

    Revista Espanola de Quimioterapia, Vol. 25, Núm. 4, pp. 269-273

2008

  1. Why not revisiting tinidazole as potential treatment of odontogenic infections?

    Revista Espanola de Quimioterapia, Vol. 21, Núm. 3, pp. 198-202

2006

  1. Actividad de cefpodoxima y otros betalactámicos orales frente a Haemophilus influenzae y Streptococcus pneumoniae con distinta sensibilidad a la penicilina

    Revista Espanola de Quimioterapia, Vol. 19, Núm. 1, pp. 39-44

  2. Influencia del desplazamiento de la unión a proteínas por ibuprofeno en la actividad de una cefalosporina de tercera generación frente a Streptococcus pneumoniae

    Revista Espanola de Quimioterapia, Vol. 19, Núm. 4, pp. 332-336

2005

  1. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model

    Journal of Antimicrobial Chemotherapy, Vol. 55, Núm. 2, pp. 209-213

  2. Situación de la cefalosporina oral de tercera generación cefditoreno pivoxil en el tratamiento de la infección comunitaria del adulto

    Revista Espanola de Quimioterapia, Vol. 18, Núm. 3, pp. 210-216

2004

  1. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin

    International Journal of Antimicrobial Agents, Vol. 24, Núm. 1, pp. 79-82

2003

  1. Opsonophagocytosis versus complement bactericidal killing as effectors following Neisseria meningitidis group C vaccination

    Infection, Vol. 31, Núm. 1, pp. 51-54

2002

  1. Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae [1]

    International Journal of Antimicrobial Agents

  2. Increase of in vitro amoxycillin bactericidal activity by clavulanic acid against Neisseria meningitis using time-kill curves [1]

    International Journal of Antimicrobial Agents

2001

  1. Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones

    Journal of Antimicrobial Chemotherapy, Vol. 48, Núm. 6, pp. 907-909

2000

  1. Ex vivo bactericidal activity against group C Neisseria meningitidis in seronegative subjects

    Infection, Vol. 28, Núm. 5, pp. 305-308

1999

  1. Does the degree of penicillin susceptibility of Streptococcus pneumoniae affect the bactericidal activity of co-amoxiclav versus oral cephalosporins at physiological concentrations? An in vitro pharmacodynamic simulation

    Journal of Chemotherapy, Vol. 11, Núm. 5, pp. 345-348

  2. In vitro bactericidal activity of peak serum concentrations of co- amoxiclav, amoxicillin and vancomycin against methicillin-resistant Staphylococcus aureus

    Revista Espanola de Quimioterapia, Vol. 12, Núm. 2, pp. 136-139

1998

  1. Effect of polymorphonuclear neutrophils on serum bactericidal activity against Streptococcus pneumoniae after amoxicillin administration

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 17, Núm. 1, pp. 40-43

  2. In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: A controlled study with vancomycin

    Antimicrobial Agents and Chemotherapy, Vol. 42, Núm. 7, pp. 1574-1577